Nevro Announces Coverage Update From Carelon Healthcare For The Treatment Of Painful Diabetic Neuropathy
Portfolio Pulse from Benzinga Newsdesk
Nevro Corp. (NYSE:NVRO) announced that Carelon Healthcare will expand coverage for spinal cord stimulation (SCS) for painful diabetic neuropathy (PDN), effective April 14. This policy change increases PDN patient coverage by nearly 43 million lives, including those under Anthem Blue Cross and other plans. Nevro's 10 kHz Therapy, an FDA-approved SCS system for PDN, will be more accessible. The expansion is supported by clinical trial data and is expected to continue with other health plans.
January 18, 2024 | 9:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nevro Corp. will benefit from Carelon Healthcare's policy expansion, which increases coverage for its 10 kHz Therapy SCS system for PDN. This expansion, effective April 14, will likely lead to increased adoption and sales of Nevro's system.
The policy change directly affects Nevro's product, the 10 kHz Therapy SCS system, by significantly increasing its potential market. Given the FDA approval and the clinical data supporting its efficacy, the expanded coverage is likely to result in increased demand and sales for Nevro, positively impacting its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100